☆ 4.8 Letter

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma

CANCER CELL (2021)

Journal

CANCER CELL

Volume 39, Issue 11, Pages 1442-1444

Publisher

CELL PRESS

DOI: 10.1016/j.ccell.2021.09.015

Keywords

-

Categories

Oncology Cell Biology

Funding

National Cancer Institute (NCI) [R01 CA244899, CA252222]
Amgen
Celgene/BMS
Karyopharm
NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) [75N93019C00051]
NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400008C, HHSN272201400006C]
NIAID [U01AI141990, U01AI150747]
JPB Foundation
Open Philanthropy Project [2020-215611 (5384)]
Serological Sciences Network (SeroNet)
National Cancer Institute, National Institutes of Health [75N91019D00024, 75N91020F00003]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Immunology

Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients

Matthijs Oyaert, Marie-Angelique De Scheerder, Sophie Van Herrewege, Guy Laureys, Sofie Van Assche, Melissa Cambron, Leslie Naesens, Levi Hoste, Karlien Claes, Filomeen Haerynck, Tessa Kerre, Steven Van Laecke, Wim Van Biesen, Peggy Jacques, Bruno Verhasselt, Elizaveta Padalko

Summary: Immunocompromised patients may show variable immune responses to the BNT162b2 mRNA vaccine against SARS-CoV-2, and the delay in humoral or cellular immune responses depends on the patient group, therapy, and individual risk factors.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection

Han-Sol Park, Janna R. Shapiro, Ioannis Sitaras, Bezawit A. Woldemeskel, Caroline C. Garliss, Amanda Dziedzic, Jaiprasath Sachithanandham, Anne E. Jedlicka, Christopher A. Caputo, Kimberly E. Rousseau, Manjusha Thakar, San Suwanmanee, Pricila Hauk, Lateef Aliyu, Natalia Majewska, Sushmita Koley, Bela Patel, Patrick Broderick, Giselle Mosnaim, Sonya L. Heath, Emily S. Spivak, Aarthi Shenoy, Evan M. Bloch, Thomas J. Gniadek, Shmuel Shoham, Arturo Casadevall, Daniel Hanley, Andrea L. Cox, Oliver Laeyendecker, Michael J. Betenbaugh, Steven M. Cramer, Heba H. Mostafa, Andrew Pekosz, Joel N. Blankson, Sabra L. Klein, Aaron A. R. Tobian, David Sullivan, Kelly A. Gebo

Summary: Benchmarks for protective immunity from infection or severe disease after SARS-CoV-2 vaccination are still being defined. In this study, the researchers compared different immune responses and viral variants in different groups, including vaccinated individuals and symptomatic patients. The findings showed that neutralizing antibody levels declined over time and were lower against the Alpha variant. Partially and fully vaccinated patients had lower neutralizing antibody levels against the parent virus compared to healthy controls. The study also found that neutralization activity against the Alpha variant was lower in the partially and fully vaccinated infected patients. Parent virus neutralization was identified as a predictive factor for breakthrough infections with the Alpha variant.

JCI INSIGHT (2022)

Add to Collection

Article Cell Biology

Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant

Ai-Ris Y. Collier, Catherine M. Brown, Katherine A. McMahan, Jingyou Yu, Jinyan Liu, Catherine Jacob-Dolan, Abishek Chandrashekar, Dylan Tierney, Jessica L. Ansel, Marjorie Rowe, Daniel Sellers, Kunza Ahmad, Ricardo Aguayo, Tochi Anioke, Sarah Gardner, Mazuba Siamatu, Lorraine Bermudez-Rivera, Michele R. Hacker, Lawrence C. Madoff, Dan H. Barouch

Summary: Vaccinated individuals who tested positive for SARS-CoV-2 Delta variant showed robust antibody and T cell responses, indicating the potential increase in population immunity through vaccination and breakthrough infections.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma

Adolfo Aleman, Morgan van Kesteren, Ariel Kogan Zajdman, Komal Srivastava, Christian Cognigni, Jacob Mischka, Lucia Y. Chen, Bhaskar Upadhyaya, Kseniya Serebryakova, Jessica R. Nardulli, Neko Lyttle, Katerina Kappes, Hayley Jackson, Charles R. Gleason, Annika Oostenink, Gianna Y. Cai, Oliver Van Oekelen, Harm van Bakel, Emilia Mia Sordillo, Carlos Cordon-Cardo, Miriam Merad, Sundar Jagannath, Ania Wajnberg, Viviana Simon, Samir Parekh

Summary: This study examines the effect of bivalent vaccines on immunocompromised patients with Multiple Myeloma (MM). The findings suggest that the bivalent vaccine provides significant protection against the Omicron variant, but some treatment methods negatively affect immune cell functioning, leading to inadequate immune responses.

EBIOMEDICINE (2023)

Add to Collection

Article Virology

Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort

Moritz M. Hollstein, Sascha Dierks, Michael P. Schoen, Armin Bergmann, Anna Abratis, Abass Eidizadeh, Sarah Kaltenbach, Julie Schanz, Uwe Gross, Andreas Leha, Andrea Kroeger, Reiner Andag, Andreas E. Zautner, Andreas Fischer, Luise Erpenbeck, Moritz Schnelle

Summary: This study compared immune responses in vaccinated individuals with and without breakthrough SARS-CoV-2 infections. It found that breakthrough infections significantly increased humoral immune response, but did not boost cellular immune response. Levels of antibodies and antibody avidity decreased with age, and females had higher antibody levels. The association between humoral and cellular immune responses observed previously was lost in individuals after breakthrough infections.

JOURNAL OF MEDICAL VIROLOGY (2023)

Add to Collection

Article Allergy

Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study

Zeynep Ece Kuloglu, Rojbin El, Gulen Guney-Esken, Yesim Tok, Zeynep Gulce Talay, Tayfun Barlas, Mert Ahmet Kuskucu, Ozgur Albayrak, Ozlem Dogan, Serap Simsek Yavuz, Kenan Midilli, Onder Ergonul, Fusun Can

Summary: This study aimed to investigate the effects of BNT162b2 (BNT) and CoronaVac (CV) boosters on the immune response of individuals who had received two doses of CV vaccination. The results showed that the neutralizing antibody levels were higher after 3 months of BNT booster compared to CV booster.

ALLERGY (2022)

Add to Collection

Article Cell Biology

Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection

Hye Won Jeong, Se-Mi Kim, Min Kyung Jung, Ji Yun Noh, Ji-Seung Yoo, Eun-Ha Kim, Young-Il Kim, Kwangmin Yu, Seung-Gyu Jang, Juryeon Gil, Mark Anthony Casel, Rollon Rare, Jeong Ho Choi, Hee-Sung Kim, Jun Hyoung Kim, Jihye Um, Chaeyoon Kim, Yeonjae Kim, Bum Sik Chin, Sungmin Jung, Jun Yong Choi, Kyoung-Ho Song, Yong-Dae Kim, Jun-Sun Park, Joon Young Song, Eui-Cheol Shin, Young Ki Choi

Summary: Omicron has become the dominant variant of SARS-CoV-2 globally and poses challenges due to its ability to evade neutralization. This study shows that neutralizing antibodies against Omicron are not detected in individuals previously infected with ancestral or past SARS-CoV-2 variants or after two-dose mRNA vaccination. However, a three-dose vaccination course induces broad neutralizing antibody responses with improved durability against different SARS-CoV-2 variants, although neutralizing antibody titers against Omicron remain low. Interestingly, among individuals with three-dose vaccination, Omicron breakthrough infection significantly enhances serum neutralizing activity against a broad spectrum of SARS-CoV-2 variants, including Omicron variants BA.1, BA.2, and BA.5. Additionally, memory T cells respond to both ancestral and Omicron spike proteins by producing cytokines, suggesting that Omicron breakthrough infection following three-dose mRNA vaccination induces pan-SARS-CoV-2 immunity that may protect against emerging SARS-CoV-2 variants of concern.

CELL REPORTS MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 mortality may be reduced among fully vaccinated solid organ transplant recipients

Micaela Sandoval, Duc T. Nguyen, Howard J. Huang, Stephanie G. Yi, R. Mark Ghobrial, A. Osama Gaber, Edward A. Graviss

Summary: This investigation found that COVID-19 mortality may be significantly reduced among immunosuppressed SOT recipients within 6 months following vaccination.

PLOS ONE (2022)

Add to Collection

Article Immunology

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Outbreak Among Fully Vaccinated Nursing Home Residents Likely Initiated by a Fully Vaccinated Staff Member - Connecticut, July-August 2021

Stephen M. Bart, Adora Harizaj, Claire L. Pearson, Tiara Conteh, Erin Grogan, Randy Downing, Hannah L. Kirking, Jacqueline E. Tate, John A. Jernigan, Vivian Leung

Summary: A COVID-19 outbreak occurred in a Connecticut nursing home during July-August 2021, involving 21 fully vaccinated residents and 10 fully vaccinated staff members. The outbreak was likely initiated by a fully vaccinated staff member and spread by other fully vaccinated individuals. Prior COVID-19 infection provided protection among vaccinated residents.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Microbiology

Inflammatory and Immune Responses during SARS-CoV-2 Infection in Vaccinated and Non-Vaccinated Pregnant Women and Their Newborns

Paola Zelini, Piera d'Angelo, Federica Zavaglio, Ehsan Soleymaninejadian, Liliana Mariani, Francesca Perotti, Mattia Dominoni, Stelvio Tonello, Pierpaolo Sainaghi, Rosalba Minisini, Daria Apostolo, Daniele Lilleri, Arsenio Spinillo, Fausto Baldanti

Summary: In this prospective study, it was found that vaccinated pregnant women and their newborns had higher levels of cytokines and immune responses after SARS-CoV-2 infection. Additionally, the newborns of vaccinated mothers had higher levels of specific antibodies. Vaccination can enhance the immune profile of pregnant women and provide immune protection to newborns.

PATHOGENS (2023)

Add to Collection

Article Virology

Stable and durable antibody responses in SARS-recovered donors vaccinated with inactivated SARS-CoV-2 vaccine

Tingting Jia, Yuankai Wu, Guancheng Liao, Yuxuan Lei, Zhengyu Wu, Fangji Yang, Jiamin Chen, Qian Xie, Chuming Luo, Yutian Chong, Huanle Luo, Yuelong Shu

Summary: Research has found that SARS-recovered individuals who received three doses of inactivated SARS-CoV-2 vaccine produce higher levels of SARS-CoV-2 neutralizing antibodies and spike-specific IgA and IgG antibodies. However, in SARS-naive individuals, the levels of neutralizing antibodies increase more rapidly after the third dose of the vaccine. Additionally, regardless of prior SARS infection, the Omicron subvariants show immune evasion. For SARS survivors, a single dose of inactivated SARS-CoV-2 vaccine provides protection against wild-type SARS-CoV-2 and early variants of concern (Alpha, Beta, Gamma, and Delta) but not against Omicron subvariants. Therefore, it is important to evaluate the type and dosage of SARS-CoV-2 vaccine for SARS survivors.

JOURNAL OF MEDICAL VIROLOGY (2023)

Add to Collection

Article Immunology

Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021

Nicolas Vignier, Vincent Berot, Nathalie Bonnave, Sandrine Peugny, Mathilde Ballet, Estelle Jacoud, Celine Michaud, Melanie Gaillet, Felix Djossou, Denis Blanchet, Anne Lavergne, Magalie Demar, Mathieu Nacher, Dominique Rousset, Loic Epelboin

Summary: An outbreak of severe acute respiratory syndrome coronavirus 2 caused by the Gamma variant infected 55% of employees at a gold mine in French Guiana, with 87% showing symptoms but no severe cases. Among fully vaccinated miners, the attack rate was 60%, while it was 75% among unvaccinated miners without a history of infection.

EMERGING INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection

Martha Sedegah, Chad Porter, Emilie Goguet, Harini Ganeshan, Maria Belmonte, Jun Huang, Arnel Belmonte, Sandra Inoue, Neda Acheampong, Allison M. W. Malloy, Monique Hollis-Perry, Belinda Jackson-Thompson, Kathy F. Ramsey, Yolanda Alcorta, Santina E. Maiolatesi, Gregory Wang, Anatolio E. Reyes, Luca Illinik, Margaret Sanchez-Edwards, Timothy H. Burgess, Christopher C. Broder, Eric D. Laing, Simon D. Pollett, Eileen Villasante, Edward Mitre, Michael R. Hollingdale

Summary: Class I- and Class II-restricted epitopes have been identified across the SARS-CoV-2 structural proteome. Vaccine-induced and post-infection T-cell responses are associated with COVID-19 recovery and protection. Vaccination with BNT162b2 or mRNA-1273 results in T cell-specific responses primarily against epitopes in the S2 subunit of the S glycoprotein. Individuals vaccinated after SARS-CoV-2 infection develop broader and greater T cell responses to S1 and S2 subunits as well as the N and M proteins.

PLOS ONE (2022)

Add to Collection

Article Virology

Determining the reliability of rapid SARS-CoV-2 antigen detection in fully vaccinated individuals

Nareshkumar Poopalasingam, Michael Korenkov, Artem Ashurov, Janina Strobel, Irina Fish, Martin Hellmich, Henning Gruell, Clara Lehmann, Eva Heger, Florian Klein

Summary: This study evaluated the performance of the Standard Q COVID-19 Ag Test in detecting SARS-CoV-2 breakthrough infections in vaccinated individuals using RT-qPCR and rapid antigen detection testing. The results showed that RADT testing remains a valuable tool in detecting breakthrough infections with high viral RNA loads.

JOURNAL OF CLINICAL VIROLOGY (2022)

Add to Collection

Article Genetics & Heredity

COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view

Ivana von Metzler, Julia Campe, Sabine Huenecke, Marc S. Raab, Hartmut Goldschmidt, Ralf Schubert, Holger F. Rabenau, Sandra Ciesek, Hubert Serve, Evelyn Ullrich

Summary: Despite severe immunodeficiency in multiple myeloma patients, a balanced immune response with activation of CD8+ and CD4+ T cells, development of T-cell memory subsets, and production of SARS-CoV-2 neutralizing antibodies allowed successful combat against COVID-19. Evaluation of immune response and antibody titers in MM patients undergoing active treatment for COVID-19 could guide decision-making for further treatment and isolation measures.

JOURNAL OF MOLECULAR MEDICINE-JMM (2022)

Add to Collection

Article Multidisciplinary Sciences

Viral immunity: Basic mechanisms and therapeutic applications-a Keystone Symposia report

Jennifer Cable, Siddharth Balachandran, Lisa P. Daley-Bauer, Arjun Rustagi, Ferrin Antony, Justin J. Frere, Jamie Strampe, Katherine Kedzierska, Judy L. Cannon, Maureen A. McGargill, Daniela Weiskopf, Robert C. Mettelman, Julia Niessl, Paul G. Thomas, Bryan Briney, Sophie A. Valkenburg, Jesse D. Bloom, Pamela J. Bjorkman, Sho Iketani, C. Garrett Rappazzo, Chelsea M. Crooks, Kali F. Crofts, Stefan Pohlmann, Florian Krammer, Andrea J. Sant, Gary J. Nabel, Stacey Schultz-Cherry

Summary: Millions of people are infected by viruses each year, which pose ongoing threats to global public health. To develop more effective tools against viruses, a comprehensive understanding of the virus itself and our immune system's response to infection is necessary. The Keystone symposium Viral Immunity: Basic Mechanisms and Therapeutic Applications, held from June 29 to July 2, 2022, brought together researchers to discuss these topics, and this report provides concise summaries from several presenters at the symposium.

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2023)

Add to Collection

Article Multidisciplinary Sciences

Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice

Robert Haupt, Lauren Baracco, Erin M. Harberts, Madhumathi Loganathan, Lucas J. Kerstetter, Florian Krammer, Lynda Coughlan, Robert K. Ernst, Matthew B. Frieman

Summary: The BECC438 and BECC470 adjuvants formulated with an influenza virus hemagglutinin (HA) protein vaccine provide enhanced protection against influenza virus in adult mouse respiratory models. Immunization with HA + BECC adjuvants also broadens the epitopes targeted on HA and increases antibody titers against the conserved HA stalk domain. Furthermore, BECC470 combined with an influenza virus HA protein antigen achieves complete protection in a aged mouse model.

SCIENTIFIC REPORTS (2023)

Add to Collection

Article Engineering, Biomedical

Nanovaccines Displaying the Influenza Virus Hemagglutinin in an Inverted Orientation Elicit an Enhanced Stalk-Directed Antibody Response

Steven J. Frey, Juan Manuel Carreno, Dominika Bielak, Ammar Arsiwala, Clara G. Altomare, Chad Varner, Tania Rosen-Cheriyan, Goran Bajic, Florian Krammer, Ravi S. Kane

Summary: Despite licensed vaccines being available, influenza still leads to significant illness and death globally. Current vaccines mainly target the head domain of the viral protein hemagglutinin (HA), but influenza viruses can easily evade this response by acquiring mutations in the head domain. This study demonstrates that nanoparticles presenting HA in an inverted orientation generate higher levels of antibodies and a broader immune response against the conserved stalk domain, providing better protection against the virus. By controlling antigen orientation, it may be possible to design nanovaccines that offer broad protection against influenza and other potential pandemic pathogens.

ADVANCED HEALTHCARE MATERIALS (2023)

Add to Collection

Article Clinical Neurology

Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy

Ilana Katz Sand, Sacha Gnjatic, Florian Krammer, Kevin Tuballes, Juan Manuel Carreno, Sammita Satyanarayan, Susan Filomena, Erin Staker, Johnstone Tcheou, Aaron Miller, Michelle Fabian, Neha Safi, Jamie Nichols, Jasmin Patel, Stephen Krieger, Stephanie Tankou, Sam Horng, Sylvia Klineova, Erin Beck, Miriam Merad, Fred Lublin

Summary: This study evaluates humoral and cellular immune responses to a third COVID-19 vaccine dose in patients on anti-CD20 therapy and S1PR modulators, including Omicron-specific assays. The results show that participants on anti-CD20 therapy have lower levels of neutralizing antibodies, particularly against the BA.1 variant, but their cellular immune responses are not significantly different from healthy controls. Participants on S1PR modulator therapy have significantly reduced levels of neutralizing antibodies and cellular immune responses. These findings have clinical implications and require further study.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Add to Collection

Article Immunology

Binding and Avidity Signatures of Polyclonal Sera From Individuals With Different Exposure Histories to Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Vaccination, and Omicron Breakthrough Infections

Gagandeep Singh, Anass Abbad, Johnstone Tcheou, Demodara Rao Mendu, Adolfo Firpo-Betancourt, Charles Gleason, Komal Srivastava, Carlos Cordon-Cardo, Viviana Simon, Florian Krammer, Juan Manuel Carreno

Summary: This study investigates the impact of exposures to SARS-CoV-2 infection and vaccine antigens on the antibody response. The results show that binding and avidity of antibodies increase with the number of exposures to infection and/or vaccination. However, cross-reactivity of the antibody response after BA.1 breakthroughs is affected by the number of prior exposures.

JOURNAL OF INFECTIOUS DISEASES (2023)

Add to Collection

Article Virology

Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination

Fatima Amanat, Jordan Clark, Juan Manuel Carreno, Shirin Strohmeier, Temima Yellin, Philip S. Meade, Disha Bhavsar, Hiromi Muramatsu, Weina Sun, Lynda Coughlan, Norbert Pardi, Florian Krammer

Summary: Seasonal coronaviruses have been circulating widely in the human population and it has been hypothesized that immunity to these viruses may provide partial protection against SARS-CoV-2 infection. COVID-19 vaccination has also been shown to boost immunity against seasonal betacoronaviruses.

JOURNAL OF VIROLOGY (2023)

Add to Collection

Article Immunology

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19

Paulina Kaplonek, Deniz Cizmeci, Gaurav Kwatra, Alane Izu, Jessica Shih-Lu Lee, Harry L. Bertera, Stephanie Fischinger, Colin Mann, Fatima Amanat, Wenjun Wang, Anthonet L. Koen, Lee Fairlie, Clare L. Cutland, Khatija Ahmed, Keertan Dheda, Shaun L. Barnabas, Qasim Ebrahim Bhorat, Carmen Briner, Florian Krammer, Erica Ollman Saphire, Sarah C. Gilbert, Teresa Lambe, Andrew J. Pollard, Marta Nunes, Manfred Wuhrer, Douglas A. Lauffenburger, Shabir A. Madhi, Galit Alter

Summary: Despite the success of COVID-19 vaccines, breakthrough infections can occur due to SARS-CoV-2 variants. The immune mediators of protection in humans are still unknown. A study on ChAdOx1 nCoV-19 (AZD1222) vaccine recipients in South Africa found different Fc-receptor-binding antibodies among different groups. Individuals who resisted COVID-19 exclusively had Fc gamma R3B-binding antibodies, while those who experienced breakthrough had enhanced IgA and IgG3 with enriched Fc gamma R2B binding. Antibodies unable to bind to Fc gamma R3B led to immune complex clearance and inflammation. The differential antibody binding to Fc gamma R3B was associated with Fc-glycosylation differences in SARS-CoV-2-specific antibodies.

NATURE IMMUNOLOGY (2023)

Add to Collection

Article Immunology

Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities

Wuji Zhang, Lukasz Kedzierski, Brendon Y. Chua, Mark Mayo, Claire Lonzi, Vanessa Rigas, Bianca F. Middleton, Hayley A. McQuilten, Louise C. Rowntree, Lilith F. Allen, Ruth A. Purcell, Hyon-Xhi Tan, Jan Petersen, Priyanka Chaurasia, Francesca Mordant, Mikhail V. Pogorelyy, Anastasia A. Minervina, Jeremy Chase Crawford, Griffith B. Perkins, Eva Zhang, Stephanie Gras, E. Bridie Clemens, Jennifer A. Juno, Jennifer Audsley, David S. Khoury, Natasha E. Holmes, Irani Thevarajan, Kanta Subbarao, Florian Krammer, Allen C. Cheng, Miles P. Davenport, Branka Grubor-Bauk, P. Toby Coates, Britt Christensen, Paul G. Thomas, Adam K. Wheatley, Stephen J. Kent, Jamie Rossjohn, Amy W. Chung, John Boffa, Adrian Miller, Sarah Lynar, Jane Nelson, Thi H. O. Nguyen, Jane Davies, Katherine Kedzierska

Summary: Kedzierska et al. found that there is an association between low production of receptor-binding domain (RBD) antibodies after mRNA vaccination and altered glycosylation of IgG before vaccination in people with comorbidities. This condition disproportionately affects Australia's First Nations peoples due to their high burden of comorbidities. The study also showed that Indigenous people, including Australian First Nations peoples, have effective immune responses to COVID-19 vaccination.

NATURE IMMUNOLOGY (2023)

Add to Collection

Article Obstetrics & Gynecology

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Titer Levels in Pregnant Individuals After Infection, Vaccination, or Both

Christina L. Marshall, Elianna Kaplowitz, Erona Ibroci, Kyle Chung, Frederieke A. J. Gigase, Molly Lieber, Mara Graziani, Sophie Ohrn, Jezelle Lynch, Juliana Castro, Rushna Tubassum, Farida Mutawakil, Rebecca Jessel, Nina Molenaar, Anna-Sophie Rommel, Rhoda S. Sperling, Elizabeth A. Howell, Hannah Feldman, Florian Krammer, Daniel Stadlbauer, Lotje D. de Witte, Veerle Bergink, Joanne Stone, Teresa Janevic, Siobhan M. Dolan, Whitney Lieb

Summary: We investigated the differences in SARS-CoV-2 antibody responses among pregnant individuals with natural immunity, vaccine-induced immunity, or combined immunity. Our study included 260 participants with seropositive results and information on mRNA vaccination and infection. We found that individuals with combined immunity had significantly higher anti-S titers compared to those with natural or vaccine-induced immunity.

OBSTETRICS AND GYNECOLOGY (2023)

Add to Collection

Article Immunology

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

Samuel Ponce-de-Leon, Martha Torres, Luis Enrique Soto-Ramirez, Juan Jose Calva, Patricio Santillan-Doherty, Dora Eugenia Carranza-Salazar, Juan Manuel Carreno, Claudia Carranza, Esmeralda Juarez, Laura E. Carreto-Binaghi, Luis Ramirez-Martinez, Georgina Paz de la Rosa, Rosalia Vigueras-Moreno, Alejandro Ortiz-Stern, Yolanda Lopez-Vidal, Alejandro E. Macias, Jesus Torres-Flores, Oscar Rojas-Martinez, Alejandro Suarez-Martinez, Gustavo Peralta-Sanchez, Hisaaki Kawabata, Irene Gonzalez-Dominguez, Jose Luis Martinez-Guevara, Weina Sun, David Sarfati-Mizrahi, Ernesto Soto-Priante, Hector Elias Chagoya-Cortes, Constantino Lopez-Macias, Felipa Castro-Peralta, Peter Palese, Adolfo Garcia-Sastre, Florian Krammer, Bernardo Lozano-Dubernard

Summary: A vaccine candidate based on a live recombinant Newcastle disease virus (NDV) expressing a stable spike protein has been evaluated. The vaccine candidate shows potential for low-cost production and can be administered intranasally to induce mucosal immunity. In a phase I clinical trial in Mexico, the vaccine was found to be safe and immunogenic at higher doses given either intramuscularly or intranasally followed by intramuscular administration.

NPJ VACCINES (2023)

Add to Collection

Article Biotechnology & Applied Microbiology

Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses

Eduard Puente-Massaguer, Annika Beyer, Madhumathi Loganathan, Iden Sapse, Juan Manuel Carreno, Goran Bajic, Weina Sun, Peter Palese, Florian Krammer

Summary: Seasonal influenza viruses cause 1 billion infections per year, with millions of severe cases and hundreds of thousands of deaths. Current influenza vaccines have varying effectiveness and target the HA and NA surface glycoproteins. This study developed a bioprocess to manufacture inactivated split cHA and mHA vaccines and a method to quantify HA with a prefusion stalk. The process demonstrated high yield and low levels of impurities, providing a basis for pre-clinical and future clinical trials.

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2023)

Add to Collection

Letter Infectious Diseases

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies

Juan Manuel Carreno, Gagandeep Singh, Viviana Simon, Florian Krammer

LANCET MICROBE (2023)

Add to Collection

Article Cell Biology

Broad spectrum SARS-CoV-2-specific immunity in hospitalized First Nations peoples recovering from COVID-19

Wuji Zhang, E. Bridie Clemens, Lukasz Kedzierski, Brendon Y. Chua, Mark Mayo, Claire Lonzi, Alexandra Hinchcliff, Vanessa Rigas, Bianca F. Middleton, Paula Binks, Louise C. Rowntree, Lilith F. Allen, Hyon-Xhi Tan, Jan Petersen, Priyanka Chaurasia, Florian Krammer, Adam K. Wheatley, Stephen J. Kent, Jamie Rossjohn, Adrian Miller, Sarah Lynar, Jane Nelson, Thi H. O. Nguyen, Jane Davies, Katherine Kedzierska

Summary: This study evaluated immune responses in Australian Indigenous peoples with COVID-19. The findings demonstrated enhanced cytokine levels, antibody responses, and memory T cell responses in Australian Indigenous peoples during the recovery phase. Additionally, the immune response patterns resembled those of non-Indigenous COVID-19 hospitalized patients.

IMMUNOLOGY AND CELL BIOLOGY (2023)

Add to Collection

Article Infectious Diseases

Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study

Hallie Cohn, Nathaniel Bloom, Gianna Y. Cai, Jordan J. Clark, Alison Tarke, Maria C. Bermudez-Gonzalez, Deena R. Altman, Luz Amarilis Lugo, Francisco Pereira Lobo, Susanna Marquez, Jin-Qiu Chen, Wenlin Ren, Lili Qin, Jennifer L. Yates, Danielle T. Hunt, William T. Lee, Shane Crotty, Florian Krammer, Alba Grifoni, Alessandro Sette, Viviana Simon, Camila H. Coelho

Summary: This study compares human immune responses to JYNNEOS vaccination and monkeypox virus infection. The results show that infection with monkeypox virus elicits robust B-cell and T-cell responses, while JYNNEOS vaccination mainly induces T-cell responses.

LANCET INFECTIOUS DISEASES (2023)

Add to Collection

Article Multidisciplinary Sciences

Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice

Eduard Puente-Massaguer, Kirill Vasilev, Annika Beyer, Madhumathi Loganathan, Benjamin Francis, Michael J. Scherm, Guha Asthagiri Arunkumar, Irene Gonzalez-Dominguez, Xueyong Zhu, Ian A. Wilson, Lynda Coughlan, Weina Sun, Peter Palese, Florian Krammer

Summary: In this study, it was shown that immunization with group 2 cHA split vaccines in combination with the CpG 1018 adjuvant elicited broadly cross-reactive antibodies against various influenza A viruses, providing immune protection.

SCIENCE ADVANCES (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.